Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xanthohumol in Critically Ill COVID-19 Patients
NCT05463393Phase 1Suspended
- Sponsor
- Medical University of Lublin
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Xanthohumol Group with Placebo Group (2 arms). Primary endpoints: Reduction in coronavirus-induced inflammatory response at 1 week and Improvement in clinical course at 28 days. Started Oct 2020; status: suspended.
02
Drugs
xanthohumol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05463393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463393.